🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: CAB-RPV LA

Found 0 matching trials

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

PHASE2

This study addresses real-world use of long-acting injectable cabotegravir/...

Status

Active Not Recruiting

Location

Yale Clinical and Community Research

Start Date

2024-08-01

Trial ID

NCT06411223

Treatments Being Tested

Collaborative drug therapy management model Cabotegravir/Rilpivirine

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

PHASE3

The overall objective of the CAB LA + RPV LA clinical development program i...

Status

Completed

Location

GSK Investigational Site

Start Date

2020-09-28

Trial ID

NCT04399551

Treatments Being Tested

CAB OLI CAB LA RPV OLI RPV LA Continuous Quality Improvement (CQI) calls

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

PHASE3

This study compares the efficacy, safety and tolerability of CAB ULA and RP...

Status

Recruiting

Location

GSK Investigational Site

Start Date

2026-06-25

Trial ID

NCT07650916

Treatments Being Tested

CAB ULA RPV ULA CAB LA RPV LA

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

PHASE3

This sub-study will assess the pharmacokinetics (PK), safety, tolerability,...

Status

Completed

Location

GSK Investigational Site

Start Date

2021-10-28

Trial ID

NCT05896761

Treatments Being Tested

Cabotegravir Injectable Suspension Rilpivirine Injectable Suspension

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

PHASE2

This study is a Phase IIb, randomized, multicentre, parallel group, open-la...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-04-28

Trial ID

NCT02120352

Treatments Being Tested

CAB Oral Tablets CAB LA ABC/3TC Oral tablets RPV Oral Tablets HAART RPV

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

PHASE4

HOLA is a prospective, randomized (1:1), hybrid type (implementation-effect...

Status

Completed

Location

Germans Trias I Pujol Hospital

Start Date

2023-09-26

Trial ID

NCT06185452

Treatments Being Tested

Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration

The Cheeky Study: A Novel Delivery System for CAB-RPV LA

This is a single-arm implementation study of a novel integrated delivery mo...

Status

Unknown

Location

Bridge HIV, San Francisco Department of Public Health

Start Date

2023-05-31

Trial ID

NCT05979714

Treatments Being Tested

Patient-centered injection site Patient-centered adherence support Provider education Improved clinic communication strategies

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

PHASE3

The First Long-Acting Injectable Regimen (FLAIR) study is being conducted t...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2016-10-27

Trial ID

NCT02938520

Treatments Being Tested

Cabotegravir (CAB) tablet Rilpivirine (RPV) tablet Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)ABC/DTG/3TC STR - Tablet DTG Tablet

Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study

N/A

This study evaluates the real-world effectiveness and safety of a long-acti...

Status

Recruiting

Location

Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases

Start Date

2026-05-12

Trial ID

NCT07370649

Treatments Being Tested

Cabotegravir Plus Rilpivirine Long-Acting Injectable

Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

PHASE3

IMPALA is a randomized, open-label, multicenter, interventional study of 54...

Status

Active Not Recruiting

Location

Jaramogi Oginga Odinga Teaching & Referral Hospital

Start Date

2022-12-08

Trial ID

NCT05546242

Treatments Being Tested

Cabotegravir/Rilpivirine Antiretroviral

Previous Next